01302.HK is the world's leading supplier of minimally invasive interventional medical devices for the treatment of cardio-cerebrovascular and peripheral vascular diseases, integrating R & D, manufacturing and sales. Founded in 1999, Xianjian Technology, headquartered in Shenzhen, China, occupies a leading position in the global congenital heart disease occluder market and is also the second largest supplier of congenital heart disease occluders in the world. Xianjian Technology has set up a number of subsidiaries and sales offices in the Netherlands, France, Slovakia, Russia, India, Beijing, Shanghai, Guangzhou, Shenzhen and Hong Kong. In November 2011, Xian Jian Technology was successfully listed on Hong Kong Exchanges and Clearing and successfully transferred from the gem to the main board of the Hong Kong Stock Exchange in November 2013. In October 2012, Medtronic signed a strategic investment agreement with Shanjian Technology, and completed its strategic investment in Shanjian Technology in January 2013. Xianjian Technology has an experienced and high-quality R & D team, focusing on the research and development of innovative cardiovascular interventional medical devices and related technologies, and conducting extensive cooperation and exchanges with well-known doctors and technical experts at home and abroad. at the same time, it has undertaken more than 40 government scientific research projects, and is a national high-tech enterprise and national postdoctoral research station. Shanjian technology products are sold to 78 countries around the world, and more than 140 dealers cover Europe, South America, Asia, Africa and other places. It is the largest supplier of congenital heart disease occluders in BRIC countries. Xianjian Technology has been committed to independent innovation and research and development of cutting-edge cardiovascular interventional medical devices, and will continue to make outstanding contributions to the development of global medical industry.